Uncategorized
Cintas Stock: A Deep Dive Into Analyst Perspectives (11 Ratings)
Latest Ratings for CTAS Date Firm Action From To Jan 2022 Morgan Stanley Maintains Equal-Weight Dec 2021 Argus Research Maintains Buy Dec 2021 Morgan Stanley Maintains Equal-Weight View More Analyst Ratings for CTAS View the Latest Analyst Ratings read more
Expert Outlook: Ultragenyx Pharmaceutical Through The Eyes Of 11 Analysts
Latest Ratings for RARE Date Firm Action From To Feb 2022 Morgan Stanley Maintains Overweight Feb 2022 JP Morgan Upgrades Neutral Overweight Feb 2022 Morgan Stanley Maintains Overweight View More Analyst Ratings for RARE View the Latest Analyst Ratings read more
What Analysts Are Saying About Celldex Therapeutics Stock
Latest Ratings for CLDX Date Firm Action From To Sep 2021 Jefferies Initiates Coverage On Buy Sep 2021 HC Wainwright & Co. Maintains Buy Sep 2021 SVB Leerink Initiates Coverage On Outperform View More Analyst Ratings for CLDX View the Latest Analyst Ratings read more
The Analyst Verdict: Valvoline In The Eyes Of 7 Experts
Latest Ratings for VVV Date Firm Action From To Mar 2022 JP Morgan Downgrades Overweight Neutral Oct 2021 Seaport Global Upgrades Neutral Buy Aug 2021 Morgan Stanley Maintains Equal-Weight View More Analyst Ratings for VVV View the Latest Analyst Ratings read more
Forecasting The Future: 4 Analyst Projections For RxSight
Latest Ratings for RXST Date Firm Action From To Aug 2021 JP Morgan Initiates Coverage On Overweight Aug 2021 B of A Securities Initiates Coverage On Buy Aug 2021 BTIG Initiates Coverage On Buy View More Analyst Ratings for RXST View the Latest Analyst Ratings read more
Where Federal Realty Investment Stands With Analysts
Latest Ratings for FRT Date Firm Action From To Feb 2022 Mizuho Maintains Buy Feb 2022 Capital One Upgrades Equal-Weight Overweight Jan 2022 Deutsche Bank Maintains Buy View More Analyst Ratings for FRT View the Latest Analyst Ratings read more